Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Revenue: 2009-2024

Historic Revenue for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to $9.5 million.

  • Lineage Cell Therapeutics' Revenue fell 2.59% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year increase of 24.05%. This contributed to the annual value of $9.5 million for FY2024, which is 6.19% up from last year.
  • Lineage Cell Therapeutics' Revenue amounted to $9.5 million in FY2024, which was up 6.19% from $8.9 million recorded in FY2023.
  • Lineage Cell Therapeutics' Revenue's 5-year high stood at $14.7 million during FY2022, with a 5-year trough of $1.8 million in FY2020.
  • Over the past 3 years, Lineage Cell Therapeutics' median Revenue value was $9.5 million (recorded in 2024), while the average stood at $11.0 million.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Revenue slumped by 48.05% in 2020, and later surged by 238.70% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Revenue (Yearly) stood at $1.8 million in 2020, then surged by 137.73% to $4.3 million in 2021, then spiked by 238.70% to $14.7 million in 2022, then crashed by 39.16% to $8.9 million in 2023, then climbed by 6.19% to $9.5 million in 2024.